2022
Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy
2015
Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa).
Leapman M, Westphalen A, Ameli N, Lawrence H, Febbo P, Cooperberg M, Carroll P. Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa). Journal Of Clinical Oncology 2015, 33: 83-83. DOI: 10.1200/jco.2015.33.7_suppl.83.Peer-Reviewed Original ResearchGenomic Prostate ScoreIntermediate-risk prostate cancerLow-risk patientsRisk prostate cancerFavorable pathologyProstate cancerMean apparent diffusion coefficientRisk patientsApparent diffusion coefficientAdverse pathologyIntermediate-risk patientsSuspicious MRI findingsProstate MRISuspicion of malignancyMultiparametric prostate MRIFive-tier scaleRT-PCR assaysMRI findingsSingle institutionMulti-parametric prostate MRIProstate biopsyDominant lesionRisk groupsMR findingsMR score